Clinical trials: Obese Non Diabetic
Non-Alcoholic Fatty Liver Disease
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
The purpose of the study is to assess the safety and tolerability of ALT-801 in diabetic and non-diabetic subjects with overweight and obese and non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT05006885
- Testing
- ALT-801
- Where
- 15 sites in United States
- Volunteers
- 95 people
- Sponsor
- Altimmune, Inc.
Obesity and Cardiovascular Risk, Insulin Resistance
Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)
Obesity is a chronic disease of global public health concern, contributing to cardiovascular disease, type 2 diabetes and certain cancers.
- Conditions
- Obesity and Cardiovascular Risk, Insulin Resistance, Obesity (Body Mass Index >30 kg/m2)
- Trial name
- MOWRI (NCT07297290)
- Testing
- Metformin
- Where
- 2 sites in Nigeria
- Volunteers
- 220 people
- Sponsor
- University Of Nigeria Teaching Hospital
Hyperinsulinemia, Insulin Resistance
EMPOWIR:Enhance the Metabolic Profile of Women With Insulin Resistance
The goal of the study is to identify and treat women with midlife weight gain who have normal blood sugars, but increased insulin levels (hyperinsulinemia) following the performance of a glucose tolerance test.
- Conditions
- Hyperinsulinemia, Insulin Resistance, Obesity
- Trial name
- EMPOWIR (NCT00618072)
- Testing
- metformin and rosiglitazone
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- New York Medical College
Diabetes, Diabetes Mellitus, Type 1
Observational Study on Levemir® in Obese Diabetic Patients
This study is conducted in Europe. The aim of this observational study is to investigate the effect of switch from other basal insulin treatments to Levemir® on body weight in obese diabetic patients.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- KILOS (NCT00849342)
- Testing
- insulin detemir
- Where
- 2 sites in Netherlands, Slovenia
- Volunteers
- 580 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus, Obesity
The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes
This research study is being performed to begin to determine the effectiveness of two dominant bariatric surgery procedures versus an intensive lifestyle intervention to induce weight loss in patients and promote improvements in…
- Trial name
- TRIABETES (NCT01047735)
- Testing
- Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Pittsburgh
Type 2 Diabetes, Diabetes
The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers
This study, conducted at the Phoenix Indian Medical Center, Phoenix, Arizona, will determine whether reducing subclinical inflammation lessens insulin resistance in healthy, obese volunteers.
- Trial name
- NCT00339833
- Testing
- Salsalate
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Obesity, Weight Reduction
Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults
This prospective, open-label, single-arm, single-center interventional pilot trial aims to evaluate the efficacy and safety of low-dose semaglutide for weight loss and cardiometabolic improvement in obese Pakistani adults without…
- Conditions
- Obesity, Weight Reduction, Cardiometabolic Risk Factors
- Trial name
- NCT07513168
- Testing
- Locally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg)
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Asian Institute Of Medical Sciences
Diabetes, Nonalcoholic Fatty Liver Disease
Effects of Exercise on Patients With Nonalcoholic Fatty Liver Disease- A Comparative Randomized Controlled Trial
background: Obesity, diabetes mellitus type II and fatty liver disease combining with low levels of physical activity are prominent health risks for mortality and morbidity.
- Conditions
- Diabetes, Nonalcoholic Fatty Liver Disease, Obesity, Exercise
- Trial name
- [PTREC] (NCT03774511)
- Testing
- High-Intensity Interval Exercise & Moderate Intensity Interval Exercise
- Where
- Egypt
- Volunteers
- 48 people
- Sponsor
- Ahlia University
Overweight , Obesity
Phase 2 Study of MWN109 Tablet for Weight-Loss Maintenance in Participants With Overweight or Obesity
This study adopted a randomized, open-label design, aiming to preliminarily explore the weight-loss maintenance effect of MWN109 tablets when administered continuously for 24 weeks in non-diabetic overweight or obese…
- Trial name
- NCT07804797
- Testing
- MWN109 1, MWN109 2
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Diabetes Mellitus, Type 2
Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet
Background: Metformin is the first drug of choice in obese patients with type-2 diabetes (T2DM) due to its antiglycaemic as well as its cardiovascular protective potentials.
- Trial name
- NCT00118950
- Testing
- Metformin, Repaglinide, Diet-only.
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Steno Diabetes Center Copenhagen
Obesity, Diabetes
Effects of High-Dose Resveratrol in Non-Diabetic Obese Males
The primary aim of our study was to examine the effects of two weeks of oral resveratrol on resting energy expenditure and insulin sensitivity in non-diabetic obese male subjects.
- Trial name
- NCT02247596
- Testing
- Resveratrol
- Where
- Singapore
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Khoo Teck Puat Hospital
Obesity; Chronic Kidney Disease; Albuminuria
Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate whether starting finerenone together with semaglutide provides an additional reduction in urinary albumin-to-creatinine ratio…
- Trial name
- NCT07849348
- Testing
- Finerenone, Semaglutide
- Volunteers
- 266 people
- Sponsor
- Peking University People's Hospital
Overweight
Effect of South Beach Diet (SBD™) Using SBD™ Products Compared to a Calorie-Restricted Diet in Women
The purpose of this study is to examine the effectiveness of the South Beach Diet™ and South Beach Diet™ products compared to a traditional calorie restricted diet.
- Trial name
- NCT00932516
- Testing
- South Beach Diet™ with South Beach Diet™ Products, South Beach Diet™, Calorie restricted diet with South Beach Diet™ Products
- Where
- 4 sites in United States
- Volunteers
- 248 people
- Sponsor
- Mondelēz International, Inc.
Diabetes Mellitus, Non-Insulin-Dependent
Effect of Laparoscopic Roux-en-Y Gastric Bypass Surgery on Non-severe Obesity With Type 2 Diabetes Mellitus
The effect of roux-en-Y gastric bypass(RYGB) on patients with type 2 diabetes mellitus(T2DM) and a body mass index(BMI)>35kg/m2 is clear.
- Trial name
- NCT02091323
- Testing
- gastric bypass surgery
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Guangzhou General Hospital of Guangzhou Military Command
Obesity, Insulin Resistance
The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects
The primary objective of this study is to determine whether MICARDIS® improves insulin sensitivity in overweight or obese, non-diabetic, normotensive subjects.
- Trial name
- NCT00146289
- Testing
- MICARDIS® (telmisartan)
- Where
- 17 sites in United States, Canada and 3 more
- Volunteers
- 138 people
- Sponsor
- Boehringer Ingelheim
Glucose Intolerance, Obesity
Clinical Trial to Assess the Effects of Candesartan on the Carbohydrate Metabolism of Obese Subjects
Hypothesis: The use of candesartan 16-32 mg/d for 6 months improves the carbohydrate metabolism, and decreases the plasmatic levels of adipocytokines and oxidative stress markers, in non diabetic, non hypertensive subjects with…
- Trial name
- ARAMIA (NCT00319202)
- Testing
- Candesartan
- Where
- Colombia
- Volunteers
- 56 people
- Sponsor
- Fundación Cardiovascular de Colombia
Obesity
Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities
We performed a multicenter, randomized, double-blind, placebo-controlled 28-week trial. 300 non-diabetic obese subjects or overweight subjects with co-morbidities were randomly assigned.
- Trial name
- NCT04487743
- Testing
- Liraglutide
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Xiangya Hospital of Central South University
Overweight, Obesity
VDR Gene Polymorphisms and Weight Loss in Non-diabetic Overweight and Obese Subjects
This is a six months intervention study in non-diabetic overweight and obese subjects. Subjects will be counseled for weight loss through diet and exercise.
- Trial name
- NCT03386331
- Testing
- diet and exercise
- Where
- India
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Diabetes Foundation, India
Obesity
Weight Loss in Pre-diabetic, Obese Women
This is a six (6) month, single center, randomized, double-blind, parallel, controlled-feeding weight-loss study comparing two dietary groups (triglyceride and olestra) in pre-diabetic obese women.
- Trial name
- NCT00686816
- Testing
- Low calorie diet, Olestra
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- Procter and Gamble
Diabetes Mellitus Type 2, Non-alcoholic Fatty Liver Disease
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients
This study involves research about an investigational medicine called Amlexanox. The reason for this study is to find out how Amlexanox can improve type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver…
- Conditions
- Diabetes Mellitus Type 2, Non-alcoholic Fatty Liver Disease, Obesity
- Trial name
- NCT01975935
- Testing
- Amlexanox
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Michigan